| Type | Investor |
| HQ | Cambridge, US |
| Founded | 1984 |
| Website | atlasventure.com |
Atlas Venture was founded in 1984 and is headquartered in Cambridge, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Atlas Venture
Peter Barrett
Partner
David Grayzel
Partner
Jason Rhodes
Partner
Jean-Francois Formela
Partner
Bruce Booth
Partner
Kevin Bitterman
Partner
Report incorrect company information
Atlas Venture Office Locations
Atlas Venture has an office in Cambridge
Cambridge, US (HQ)
400 Technology Square
Report incorrect company information
Atlas Venture Investment Portfolio
Stage Distribution
Top Sectors Distribution
Round Size Distribution
Report incorrect company information
Atlas Venture News and Updates
September 27, 2018
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture
CAMBRIDGE, Mass., Sept. 27, 2018 /PRNewswire/ -- Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital...
June 29, 2017
Atlas Venture wraps up 11th fund at $350 mln
Cambridge, Massachusetts-based Atlas Venture, an early-stage venture firm, has closed its oversubscribed 11th fund at $350 million. Altas Ventures invests in biotech startups.
Report incorrect company information
Atlas Venture Blogs
October 11, 2018
Targeting Aging Comes Of Age
We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new therapies actionable for the first time. This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. Read more.
The post Ta…
October 09, 2018
Bring Your A-Game for BD
As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is with experience. So, I’d like to share some of my experiences doing BD from various vantage points, with the hope that it might help you jump start the career of anyone interested in BD. …
October 05, 2018
Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market quickly, creating significant downwa…
October 01, 2018
Biotech Climate Change
When I first moved from the UK to the US, I told my parents that there was more biotech VC investment in Cambridge, MA each quarter than there was in the whole of the UK in a year. Since then, my mother has been cutting ‘biotech is booming’ articles out of British newspapers to temptRead More »
The …
September 27, 2018
Atlas, F-Prime provide launch money for Akrevia — a little biotech with big plans to design better drugs
A couple of veteran drug developers are guiding a stealthy startup dubbed Akrevia Therapeutics out into the open today after a pair of high-profile biotech investors blessed the operation with a $30 million launch round. Read more.
The post Atlas, F-Prime provide launch money for Akrevia — a little …
September 24, 2018
The Rising Tide Of Biotech IPO Valuations
The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a six-year window for biotech IPOs. Read more.
The post The Ri…
Atlas Venture Company Life and Culture
Report incorrect company information